Company Data
| Last traded |
R29,074.19 |
| Change |
R-63.65 |
| % Change |
-0.22% |
| Cumulative volume |
93.53m |
| Market cap |
R0.00 |
| Last traded |
R63.23 |
| Change |
R-0.16 |
| % Change |
-0.25% |
| Cumulative volume |
350,774 |
| Market cap |
R11.05bn |
| Last traded |
R118.40 |
| Change |
R-1.60 |
| % Change |
-1.33% |
| Cumulative volume |
1.39m |
| Market cap |
R51.74bn |
Related Articles
Top Stories
May 25 2012 13:58
The costs of the first phase of the Gauteng Freeway Improvement Project have increased significantly to almost R90bn, according to a report.
May 25 2012 19:13
Uncertainty over the future of the euro zone returned to push the rand down against the dollar.
May 24 2012 17:31
The Reserve Bank will maintain current interest rates, and a considerable reduction in the local petrol price is anticipated, says governor Gill Marcus.
Johannesburg - Aspen Pharmacare Holdings [JSE:APN], Africa's
biggest generic drug maker, posted a 20% rise in full-year profit as its
international expansion plan pays off.
Aspen, 19% owned by Britain's GlaxoSmithKline, said
normalised diluted headline earnings per share (Heps) totalled 523.3 cents in the year
to end-June compared with 437.7c a year earlier.
The company said Heps was adjusted for transaction
costs.
Aspen bought the manufacturing arm of Australia's Sigma
Pharmaceuticals during the period for $887m.
"Revenue and profit contributions from the group's
businesses outside of South Africa will exceed that of the South African
business for the first time," the company said.
Aspen, which has overshadowed its closest domestic rival
Adcock Ingram Holdings [JSE:AIP] with its push into international markets, is one of companies set
to gain as drugs worth $100bn lose patent protection over the next three years.
Shares in the company, which are down about 5% so far this
year, rose 2.4% to R89.09 by 11:34 GMT, outpacing a flat JSE Top 40 -
(Tradeable) [JSE:J200] blue chip index.